Nose to brain delivery of Efavirenz nanosuspension for effective neuro AIDS therapy: in-vitro, in-vivo and pharmacokinetic assessment
Smita P. Kakad, Sanjay J. Kshirsagar
Abstract
study on Wistar rat model reveals drug transport to the CNS after nasal administration. Pharmacokinetic parameters and drug targeting potential of 99.46 % suggest direct nose to brain transport of Efavirenz nanoparticle. Results reveal that nose to brain delivery of Efavirenz is the best possible alternative for neuro -AIDS treatment.
Topics & Concepts
EfavirenzPharmacokineticsPharmacologyIn vivoMedicineAntiretroviral therapyHuman immunodeficiency virus (HIV)VirologyBiologyBiotechnologyViral loadHIV Research and TreatmentHIV/AIDS drug development and treatmentRNA Interference and Gene Delivery